Invitron Corp. and SmithKline Beckman Corp. announced...

Invitron Corp. and SmithKline Beckman Corp. announced a preliminary agreement under which Invitron will manufacture soluble T4, a potential therapy against acquired immune deficiency syndrome, and other biopharmaceutical products for Philadelphia-based SmithKline Beckman. This business collaboration, with its combination of license fees, manufacturing commitments, technology exchange and initial equity investment, has a value of approximately $21 million. To accommodate the project, Invitron will modify its St. Louis manufacturing facility during the next two years to create a separate unit for SmithKline Beckman’s products.